Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug
As per the agreement, Pfizer will invest $350m in Arvinas, representing about 7% of the stake.
News
COVID-19 vaccine market set to reach $19.5bn by 2026 – register for free webinar
An upcoming webinar will focus on what will happen in the Covid-19 vaccine market across...
Roche records 8% increase in group sales for H1 2021
Sales in the Pharmaceuticals Division dropped by 3% in H1 2021 due to the impact...
Pharmaceutical Technology Excellence Awards 2021 – SUBMIT YOUR WORK NOW
The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the industry. The...
Innovation’s drug shows antiviral activity against Covid-19 in study
Brilacidin is currently being assessed in a Phase II clinical trial in hospitalised patients with moderate-to-severe...
AstraZeneca concludes Alexion acquisition for $39bn
Alexion’s complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases.
Johnson & Johnson reports 27.1% increase in Q2 2021 sales
The company expects $2.5bn to $3.3bn in global sales from its Covid-19 vaccine this year.
Pfizer and Biovac partner to produce Covid-19 vaccine in Africa
Biovac will leverage Pfizer-BioNTech’s vaccine supply chain and production network for manufacturing and delivery activities.
Takeda expands Covid-19 vaccine supply deal with Moderna
Moderna will deliver 50 million additional doses of its Covid-19 vaccine or variant-specific booster shot next year.
Three drug distributors to pay $1.1bn to settle opioid claims by New York
McKesson, Cardinal Health and Amerisource Bergen Drug will be removed from the opioid lawsuit underway in the New York court.
Japan approves Roche-Regeneron’s Ronapreve for Covid-19 treatment
The approval is based on a Phase I trial of the antibody combination in Japanese participants and a global Phase III trial.
